Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, effectively treats various hematologic malignancies including many B-cell lymphomas, but atrial fibrillation can occur in 4–16% of patients on ibrutinib [66]. Here, BTK is linked to B-cell non-Hodgkin lymphoma.